January 26, 2009
FluoroPharma, Inc. announced today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, cover...
Read More...
September 8, 2008
FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma’s founder and Chief Scientific Advisor, will re...
Read More...
July 23, 2008
FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) mark...
Read More... |
Shaping the Future of Molecular PET Imaging
FluoroPharma is developing breakthrough molecular imaging agents for positron emission tomography (PET) and fluorescence imaging that will fulfill critical unmet medical needs. The company’s agents will give clinicians important tools for the detection and assessment of pathology before clinical manifestations of disease.
|
